<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=412980&amp;fmt=gif">
LSX-Blog.png

Something Powerful

Tell The Reader More

The headline and subheader tells us what you're offering, and the form header closes the deal. Over here you can explain why your offer is so great it's worth filling out a form for.

Remember:

  • Bullets are great
  • For spelling out benefits and
  • Turning visitors into leads.

World-first accreditation to out-of-this-world app...

Key learnings: Oxford-based Oxehealth has secured medical device accreditat...

Read More

Investorview: Propelling life science innovation f...

Denmark’s Novo Seeds was established in 2007 in order to identify promising...

Read More

Gates Foundation funding for DelSiTech’s silica-ba...

Key learnings: DelSiTech has been awarded significant grant funding from th...

Read More

A Right Pain in the Peripheries? The Supreme Court...

Summary

Read More

Medius Deal Watch: September-October 2018

There was much speculation last year that the US tax cuts that favoured the...

Read More

AI update: medical software and pre-emption

In light of the rapidly expanding field of medical software technology, and...

Read More

Lifestars Awards 2018 celebrate life science succe...

LSX (formerly Biotech and Money) hosted the Lifestars Awards at the Honoura...

Read More

Artificial intelligence and machine learning in he...

Artificial intelligence (AI), particularly machine learning (ML), is alread...

Read More

€79m Series C pushes Galecto Biotech’s pipeline in...

Key learnings: Ysios Capital and OrbiMed led Galecto Biotech’s €79 million ...

Read More

Addressing emerging themes in life science IP

Marks & Clerk’s intellectual property (IP) summit in Cambridge on 16 Octobe...

Read More

Driving developments to defeat ageing: Q&A with Au...

In February 2019, key stakeholders in the growing longevity industry will c...

Read More

Rethinking the growth capital challenge in UK life...

Investors, entrepreneurs and deal makers in the UK life sciences industry m...

Read More

Add Your Response